Paid Clinical Trials Fort Wayne

Discover 155 paid clinical trials in Fort Wayne, Indiana. Search by condition or phase to find a research study near you that matches your needs across various therapeutic areas.

Filter

Filter results

Results: 155

Sacituzumab Tirumotecan (MK-2870) Plus Pembrolizumab Versus TPC in TNBC Who Did Not Achieve pCR (MK-2870-012)Sacituzumab Tirumotecan (MK-2870) Plus Pembrolizumab Versus TPC in TNBC Who Did Not Achieve pCR (MK-2870-012)

Recruiting

PHASE3

Sponsor:

Merck Sharp & Dohme LLC

Location:

Fort Wayne IN, Royal Oak MI, Skokie IL, Zanesville OHshow 29 more

Code:

NCT06393374

Conditions

Triple-Negative Breast Cancer

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Interventions

Pembrolizumab

Sacituzumab tirumotecan

Capecitabine

Study of Navtemadlin as Maintenance Therapy in TP53WT Advanced or Recurrent Endometrial CancerStudy of Navtemadlin as Maintenance Therapy in TP53WT Advanced or Recurrent Endometrial Cancer

Recruiting

PHASE2

PHASE3

Sponsor:

Kartos Therapeutics, Inc.

Location:

Fort Wayne IN, Indianapolis IN, Columbus OH, Hinsdale ILshow 17 more

Code:

NCT05797831

Conditions

Endometrial Cancer

Eligibility Criteria

Sex: Female

Age: 18+

Healthy Volunteers: Not accepted

Interventions

Navtemadlin

Navtemadlin Placebo

A 12-Month Study of Lasmiditan (LY573144) Treatment in Children Aged 6 to 17 With MigraineA 12-Month Study of Lasmiditan (LY573144) Treatment in Children Aged 6 to 17 With Migraine

Recruiting

PHASE3

Sponsor:

Eli Lilly and Company

Location:

Fort Wayne IN, Indianapolis IN, East Lansing MI, Cincinnati OHshow 73 more

Code:

NCT04396574

Conditions

Migraine

Eligibility Criteria

Sex: All

Age: 6 - 17

Healthy Volunteers: Not accepted

Interventions

Lasmiditan

Testing the Effectiveness of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) With One Anti-cancer Targeted Drug (Cabozantinib) for Rare Genitourinary TumorsTesting the Effectiveness of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) With One Anti-cancer Targeted Drug (Cabozantinib) for Rare Genitourinary Tumors

Recruiting

PHASE2

Sponsor:

National Cancer Institute (NCI)

Location:

Lima OH, Greenville OH, Findlay OH, Perrysburg OHshow 368 more

Code:

NCT03866382

Conditions

Bladder Adenocarcinoma

Bladder Clear Cell Adenocarcinoma

Bladder Mixed Adenocarcinoma

Bladder Neuroendocrine Carcinoma

Bladder Small Cell Neuroendocrine Carcinoma

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Interventions

Biospecimen Collection

Bone Scan

Cabozantinib S-malate

Computed Tomography

Echocardiography

Open-Label Umbrella Study To Evaluate Safety And Efficacy Of Elacestrant In Various Combination In Patients With Metastatic Breast CancerOpen-Label Umbrella Study To Evaluate Safety And Efficacy Of Elacestrant In Various Combination In Patients With Metastatic Breast Cancer

Recruiting

PHASE1

PHASE2

Sponsor:

Stemline Therapeutics, Inc.

Location:

Fort Wayne IN, Detroit MI, Chicago IL, Madison WIshow 37 more

Code:

NCT05563220

Conditions

Breast Cancer

Metastatic Breast Cancer

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Interventions

Elacestrant

Alpelisib

Everolimus

Ribociclib

Palbociclib

SAVE-FistulaS: the SelfWrap-Assisted ArterioVEnous Fistulas StudySAVE-FistulaS: the SelfWrap-Assisted ArterioVEnous Fistulas Study

Recruiting

Sponsor:

VenoStent

Location:

Fort Wayne IN, Columbia MO, Charlotte NC, Raleigh NCshow 6 more

Code:

NCT06001827

Conditions

Chronic Kidney Diseases

End Stage Renal Disease

Arteriovenous Fistula

Hemodialysis Access Failure

ESRD

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Interventions

SelfWrap Bioabsorbable Perivascular Wrap

Untreated AVF Control

Selinexor in Maintenance Therapy After Systemic Therapy for Participants With p53 Wild-Type, Advanced or Recurrent Endometrial CarcinomaSelinexor in Maintenance Therapy After Systemic Therapy for Participants With p53 Wild-Type, Advanced or Recurrent Endometrial Carcinoma

Recruiting

PHASE3

Sponsor:

Karyopharm Therapeutics Inc

Location:

Goshen IN, South Bend IN, Sylvania OH, Indianapolis INshow 71 more

Code:

NCT05611931

Conditions

Endometrial Cancer

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Interventions

Selinexor

Matching Placebo for selinexor

Efficacy and Safety of Remibrutinib Compared to Teriflunomide in Participants With Relapsing Multiple Sclerosis (RMS)Efficacy and Safety of Remibrutinib Compared to Teriflunomide in Participants With Relapsing Multiple Sclerosis (RMS)

Recruiting

PHASE3

Sponsor:

Novartis Pharmaceuticals

Location:

Fort Wayne IN, Westerville OH, Detroit MI, Chicago ILshow 62 more

Code:

NCT05147220

Conditions

Relapsing Multiple Sclerosis

Eligibility Criteria

Sex: All

Age: 18 - 55

Healthy Volunteers: Not accepted

Interventions

Remibrutinib

Teriflunomide

Bupropion to Reduce Cancer Related Fatigue in Cancer SurvivorsBupropion to Reduce Cancer Related Fatigue in Cancer Survivors

Recruiting

PHASE3

Sponsor:

University of Rochester NCORP Research Base

Location:

Lima OH, Greenville OH, Niles MI, Findlay OHshow 290 more

Code:

NCT03996265

Conditions

Be Diagnosed With Cancer and Have Completed Systemic Therapy

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Interventions

Bupropion Hydrochloride Controlled-release

Placebo Administration

Quality-of-Life Assessment

Questionnaire Administration

Study of Subcutaneous Epcoritamab in Combination With Intravenous Rituximab and Oral Lenalidomide (R2) to Assess Adverse Events and Change in Disease Activity in Adult Participants With Previously Untreated Follicular LymphomaStudy of Subcutaneous Epcoritamab in Combination With Intravenous Rituximab and Oral Lenalidomide (R2) to Assess Adverse Events and Change in Disease Activity in Adult Participants With Previously Untreated Follicular Lymphoma

Recruiting

PHASE3

Sponsor:

Genmab

Location:

Fort Wayne IN, Maumee OH, Cincinnati OH, Chicago ILshow 33 more

Code:

NCT06191744

Conditions

Follicular Lymphoma (FL)

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Interventions

Epcoritamab

Prednisone

Rituximab

Lenalidomide

Doxorubicin